Susceptibility testing of extensively drug-resistant and pre-xtensively drug-resistant mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2522-2525

  Ahmed, Imran ^a   Jabeen, Kauser ^a   Inayat, Raunaq ^a   Hasan, Rumina ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMOXICILLIN PLUS CLAVULANIC ACID; LEVOFLOXACIN; LINEZOLID; OFLOXACIN;

AGAR DIFFUSION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PAKISTAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ACETAMIDES; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; OXAZOLIDINONES; PAKISTAN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84877854666     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02020-12     Document Type: Article

References (31)

1. World Health Organization. 2011. Global tuberculosis control. Document WHO/HTM/TB/2011.16. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2009. Global tuberculosis control: Epidemiology, strategy, financing. Document WHO/HTM/TB/2009.411. World Health Organization, Geneva, Switzerland.
3. Hasan R, Jabeen K, Ali A, Rafiq Y, Laiq R, Malik B, Tanveer M, Groenheit R, Ghebremichael S, Hoffner S, Hasan Z. 2010. Extensively drug-resistant tuberculosis, Pakistan. Emerg. Infect. Dis. 16:1473-1475.
4. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
5. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, Kim EK, Lee KM, Lee SS, Park JS, Koh WJ, Lee CH, Shim TS. 2010. Treatment outcomes and survival based on drug resistance patterns in multidrugresistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:113-119.
6. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J. 2003. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: Preliminary results of a retrospective study from Hong Kong. Chest 124:1476-1481.
7. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin. Infect. Dis. 51:6-14.
8. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-192.
9. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, Furin JJ, Fitzmaurice GM, Alcantara Viru FA, Appleton SC, Bayona JN, Bonilla CA, Chalco K, Choi S, Franke MF, Fraser HS, Guerra D, Hurtado RM, Jazayeri D, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Munoz M, Palacios E, Sanchez E, Sloutsky A, Becerra MC. 2008. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359: 563-574.
10. Shakoor S, Ahsan T, Jabeen K, Raza M, Hasan R. 2010. Use of pnitrobenzoic acid in 7H10 agar for identification of Mycobacterium tuberculosis complex: A field study. Int. J. Tuberc. Lung Dis. 14:1644-1646.
11. Koneman EW, Allen SD, Janda WM, Schereckenberger PC. 2005. Color atlas and textbook of diagnostic microbiology, 6th ed. Lippincott, Philadelphia, PA.
12. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes; approved standard. Document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.
14. Schon T, Jureen P, Chryssanthou E, Giske CG, Sturegard E, Kahlmeter G, Hoffner S, Angeby KA. 2011. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 15:502-509.
15. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: Associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865.
16. World Health Organization. 2008. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. Document WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland.
17. Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegard E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schon T. 2010. Wild-typeMICdistributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 65:946-952.
18. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. 2009. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13:79-83.
19. Rafiq Y, Jabeen K, Hasan R, Jafri S, Laiq R, Malik F, Mangi R, Channa A, Hasan Z. 2011. Fluoroquinolone resistance among Mycobacterium tuberculosis strains from Karachi, Pakistan: Data from community-based field clinics. Antimicrob. Agents Chemother. 55:929-930.
20. Butt ZA, Gilani AH, Nanan D, Sheikh AL, White F. 2005. Quality of pharmacies in Pakistan: A cross-sectional survey. Int. J. Qual. Health Care 17:307-313.
21. Jabeen K, Nizamuddin S, Irfan S, Khan E, Malik F, Zafar A. 2011. Increasing trend of resistance to penicillin, tetracycline, and fluoroquinolone resistance in Neisseria gonorrhoeae from Pakistan (1992-2009). J. Trop. Med. 2011:960501.
22. Hasan R, Zafar A, Abbas Z, Mehraj V, Malik F, Zaidi A. 2008. Antibiotic resistance among Salmonella enterica serovars Typhi and Paratyphi A in Pakistan (2001-2006). J. Infect. Developing Countries 2:289-294.
23. Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC. 2008. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob. Agents Chemother. 52:2226-2227.
24. Richter E, Rusch-Gerdes S, Hillemann D. 2007. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1534-1536.
25. Koh W, Kwon OJ, Gwak H, Chung JW, Cho S, Kim WS, Shim TS. 2009. Daily 300-mg dose of linezolid for the treatment of intractable multidrugresistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388-391.
26. Varshochi M, Rastgar Raffi MHA, Nagili B. 2006. In vitro susceptibility of Mycobacterium tuberculosis to amoxicillin-clavulanate. Iranian J. Clin. Infect. Dis. 1:121-125.
27. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. 2004. Augmentin (amoxicillin/clavulanate) in the treatment of communityacquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl 1):i3-i20.
28. Chambers HF, Kocagoz T, Sipit T, Turner J, Hopewell PC. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26:874-877.
29. Donald PR, Sirgel FA, Venter A, Parkin DP, Van de Wal BW, Barendse A, Smit E, Carman D, Talent J, Maritz J. 2001. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis. 33:466-469.
30. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. 1991. Amoxicillinclavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99:1025-1026.
31. Kim SJ. 2005. Drug susceptibility testing in tuberculosis: Methods and reliability of results. Eur. Respir. J. 25:564-569.